-
Validation of Dyskinesia Rating Scales
… that occur with newer treatments. Patients will benefit from this new international standard, because they can … the likelihood and magnitude of anticipated improvement from different dyskinesia treatments, whether medical or …
-
Evaluation of LRRK2 Inhibitors in the LRRK2 Drosophila PD Model
… be evaluated to determine if these drugs can provide relief from the symptoms and perhaps rescue the dopaminergic … in the transgenic fly model will protect dopamine neurons from cell death and preserve motor function. If these …
-
Treating speech disorders in patients with Parkinson's disease using altered auditory feedback
… with a shift in pitch while they spoke. The delay ranged from 50-220 ms and their pitch shifted up or down from 500-2,000 Hz. For each patient, a specific combination …
-
Validation of Sirtuin 2 Deacetylase as a Therapeutic Target in Parkinson’s disease
… of Parkinson’s disease. The efficacious molecules, emerging from the animal trials, will be subjected for further … read-out, and remain to be elucidated. Thus, the results from the selected RNAi target-validation approach was not …
-
Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease
… used by the brain. Freezing of gait is believed to result from norepinephrine deficiency due to degeneration of a … been ascertained, but final results are pending. Results from this study have been published: A.J. Espay, A.K. …
-
Understanding the Molecular and Functional Changes of CB1/D2/A2A Receptor Complexes in the Hemi-parkinsonian Pre-clinical Model
… Future therapies in Parkinson’s disease (PD) may derive from the existence of intramembrane heteromeric receptor … will be used as the animal model of PD. Striatal tissue from naive (control rats); 6-OHDAtreated or sham-treated …